ALS drug shows promise in targeting glioblastoma stem cells
Mădălina Grigore
University of Ottawa Oct 17 2024 Glioblastoma is the most common – and the most malignant – primary brain tumour in adults. It's aggressive and incurable. Even with treatment including surgical removal and chemotherapy, the median survival for patients is just 18 months. Now, innovative new research led by Dr. Arezu Jahani-Asl, Canada Research Chair in Neurobiology of Disease at the University of Ottawa, provides highly compelling evidence that a drug used to slow the progression of the disease
din zilele anterioare